Abstract
There is considerable evidence that T-helper 2 (Th2) cells play a central role in the pathogenesis of allergic diseases such as bronchial asthma, hay fever or food allergy. The differentiation of naïve T cells into Th2 cells producing a specific pattern of cytokines is tightly controlled and regulated by transcription factors. Thus down-regulation of mRNAlevels of a single transcription factor leads to a “knock-down” of several mediators simultaneously, representing an advantage compared to earlier approaches involving down-regulation of one intercellular inflammatory mediator, which is unlikely to influence all pathophysiological aspects of the disease. We review the impact of specific and master transcription factors involved in Th2 cell commitment and evaluate approaches for the down-regulation of these proteins by degradation of their mRNA using nucleic-acid based technologies including antisense oligonucleotides, ribozymes, DNAzymes, decoys oligonucleotides and RNA interference.
Keywords: Nucleic-acid based technology, antisense, therapeutic tool, transcription factor, allergy, asthma
Current Pharmaceutical Design
Title: Treatment of Allergic Asthma by Targeting Transcription Factors Using Nucleic-Acid Based Technologies
Volume: 12 Issue: 25
Author(s): Serdar Sel, Wolfgang Henke, Alexander Dietrich, Udo Herz and Harald Renz
Affiliation:
Keywords: Nucleic-acid based technology, antisense, therapeutic tool, transcription factor, allergy, asthma
Abstract: There is considerable evidence that T-helper 2 (Th2) cells play a central role in the pathogenesis of allergic diseases such as bronchial asthma, hay fever or food allergy. The differentiation of naïve T cells into Th2 cells producing a specific pattern of cytokines is tightly controlled and regulated by transcription factors. Thus down-regulation of mRNAlevels of a single transcription factor leads to a “knock-down” of several mediators simultaneously, representing an advantage compared to earlier approaches involving down-regulation of one intercellular inflammatory mediator, which is unlikely to influence all pathophysiological aspects of the disease. We review the impact of specific and master transcription factors involved in Th2 cell commitment and evaluate approaches for the down-regulation of these proteins by degradation of their mRNA using nucleic-acid based technologies including antisense oligonucleotides, ribozymes, DNAzymes, decoys oligonucleotides and RNA interference.
Export Options
About this article
Cite this article as:
Sel Serdar, Henke Wolfgang, Dietrich Alexander, Herz Udo and Renz Harald, Treatment of Allergic Asthma by Targeting Transcription Factors Using Nucleic-Acid Based Technologies, Current Pharmaceutical Design 2006; 12 (25) . https://dx.doi.org/10.2174/138161206778194150
DOI https://dx.doi.org/10.2174/138161206778194150 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Hot Topic: New Drug Targets for the Treatment of Asthma (Guest Editor: D. Knight)]
Current Drug Targets Medicinal Chemistry of N-Acylhydrazones: New Lead-Compounds of Analgesic, Antiinflammatory and Antithrombotic Drugs
Current Medicinal Chemistry C/EBP Transcription Factors in Lung Disease
Current Respiratory Medicine Reviews Mitogen-Activated Protein Kinases: New Molecular Targets for Pharmacological Treatment of Inflammatory Lung Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Gene Therapy-Mediated Modulation of Immune Processes in the Central Nervous System
Current Pharmaceutical Design Endothelin Receptor Antagonists: A New Therapeutic Option for Improving the Outcome after Solid Organ Transplantation?
Current Vascular Pharmacology The Role of T-Helper Cells in Atherosclerosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Sulfated Oligosaccharides: New Targets for Drug Development?
Current Medicinal Chemistry Antioxidative Properties of Flavonoids
Current Organic Chemistry Interleukin-17A: A Potential Therapeutic Target in Chronic Lung Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Enteric Ecosystem Disruption in Autism Spectrum Disorder: Can the Microbiota and Macrobiota be Restored?
Current Pharmaceutical Design Airway Smooth Muscle Responsiveness: The Origin of Airway Hyperresponsiveness in Asthma?
Current Respiratory Medicine Reviews Protein Kinase C-theta Inhibitors: A Novel Therapy for Inflammatory Disorders
Current Pharmaceutical Design Significance of Pharmacogenetics and Pharmacogenomics Research in Current Medical Practice
Current Drug Metabolism Enkephalinase Inhibitors: Potential Agents for the Management of Pain
Current Drug Targets Regulation of Eosinophil Migration and Th2 Cell Function by IL-5 and Eotaxin
Current Drug Targets - Inflammation & Allergy Structure-Function Relationships of Plasminogen Activator Inhibitor-1 and Its Potential as a Therapeutic Agent
Current Drug Targets Fractal Analysis of the Bone Marrow in Myelodysplastic Syndromes
Current Bioinformatics Platelets and Vascular Risk: An Option for Treatment
Current Pharmaceutical Design The Emerging Diabetes Online Community
Current Diabetes Reviews